Telix Pharmaceuticals (ASX:TLX) said that the US Food and Drug Administration has approved its New Drug Application for Gozellix, the company's prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agent for prostate cancer, according to a Friday filing with the Australian bourse.
Gozellix is designed for PET scanning of PSMA-positive lesions in men with prostate cancer, the filing said.
The agent offers a six-hour shelf life and extended distribution range compared to existing gallium-based imaging agents, improving access to PET scanners which currently cannot use other PSMA imaging products, filing added.
Telix expects Gozellix to expand access by qualifying for full reimbursement with reduced or no patient co-insurance, which will benefit underserved populations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.